



Dear Valued Client,

You may have noticed in recent documentation that the name of our organization has changed. ACM Global Laboratories is pleased to announce, effective 25th June 2021, the rebranding of ABS Laboratories to ACM Bioanalytical Services.

Founded over two decades ago by scientists Drs. Colin Feyerabend and Mira Doig, PhD, ABS was purchased by ACM in 2018 as part of a strategic growth initiative, with a goal of expanding its collection of domestic and international laboratories focused on bioanalytical, toxicology and central lab testing.

The service line, ACM Bioanalytical Services, will maintain all of its talented employees, quality management systems, GLP/GCP accreditation and grow based on client needs and company growth. For current and onboarding clients of ABS and ACM, this rebrand will not have any affect, and your designated Study Directors and Project Managers will remain the same.

The combined technology and expertise provided by ACM and ABS has allowed the joint venture an opportunity to flourish, while ensuring patient centricity in trial design, thanks to direct access to an expert scientific team.

Thank you for your continued partnership.

Tom Mueller
Chief Commercial Officer